Last updated: August 2, 2026
Exelixis, Inc. v. Cipla Ltd., No. 1:23-cv-00287, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Cipla’s proposed generic version of Cabometyx, the branded cabozantinib tablet marketed by Exelixis. Exelixis alleged that Cipla’s abbreviated new drug application, or ANDA, infringed multiple Cabometyx patents. The case was resolved by a negotiated dismissal rather than a public trial judgment. The publicly available docket does not disclose the settlement’s commercial terms or Cipla’s authorized launch date.
What drug and regulatory pathway were involved?
The litigation concerned Cabometyx tablets, whose active ingredient is cabozantinib malate. Cabometyx is approved for oncology indications including renal cell carcinoma, hepatocellular carcinoma and differentiated thyroid cancer. Exelixis holds the principal U.S. commercialization rights and markets the product through its oncology portfolio.
Cipla proceeded through the ANDA pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. Its Paragraph IV certification asserted that one or more patents listed for Cabometyx were invalid, unenforceable or would not be infringed by Cipla’s proposed product.
The filing of Exelixis’s infringement complaint triggered the statutory 30-month stay applicable to FDA approval of the challenged ANDA, subject to earlier resolution or a court order. The public case record identifies the dispute as a patent infringement action arising from Cipla’s ANDA filing, but does not establish that FDA approved Cipla’s ANDA during the litigation.
Cabometyx regulatory profile
| Item |
Publicly reported position |
| Brand |
Cabometyx |
| Active ingredient |
Cabozantinib malate |
| Dosage form |
Oral tablets |
| Applicant and marketer |
Exelixis, Inc. |
| Regulatory pathway for Cipla |
ANDA with Paragraph IV certification |
| Litigation forum |
U.S. District Court for the District of Delaware |
| Case number |
1:23-cv-00287 |
| Filing year |
2023 |
| Resolution |
Negotiated dismissal |
| Public settlement terms |
Not disclosed in the docket materials reviewed |
Sources: FDA, Approved Drug Products with Therapeutic Equivalence Evaluations; Exelixis v. Cipla docket.
What patents protected Cabometyx in Exelixis v. Cipla?
Exelixis’s Cabometyx patent estate has included composition-of-matter, pharmaceutical-composition, crystalline-form and method-of-treatment patents. The complaint in the Cipla action should be read together with the patents listed in the FDA Orange Book for Cabometyx at the time of the ANDA litigation.
The core patent families associated with cabozantinib include the following:
| Patent family or patent category |
Principal protection |
Business relevance |
| Early cabozantinib compound patents |
Cabozantinib compounds and oncology treatment methods |
Foundational protection, with earlier expiration exposure |
| Cabozantinib malate patents |
Active pharmaceutical ingredient and salt-related protection |
May restrict substitution with a different chemical form |
| Formulation patents |
Tablet compositions, excipients and dosage formulations |
Can create separate infringement risk after compound claims expire |
| Method-of-use patents |
Treatment of specified cancers and patient populations |
Relevant where the ANDA label includes protected indications |
| Later-issued Cabometyx patents |
Specific formulations, dosing regimens or treatment methods |
Can extend litigation and delay generic commercialization |
The Orange Book listing must be distinguished from the entire Exelixis patent estate. A patent may cover cabozantinib or a treatment method without being listed for a particular approved product. Conversely, an Orange Book-listed patent can be important even when it does not cover every possible use of the active ingredient.
What were the likely infringement theories?
The principal Hatch-Waxman theories in a Cabometyx case would typically involve:
- Direct infringement based on the composition of Cipla’s proposed tablets.
- Infringement of pharmaceutical-composition claims based on the specified excipients, dosage strengths or tablet architecture.
- Infringement of method-of-treatment claims if Cipla’s proposed labeling included a patented indication.
- Induced infringement based on instructions for use in the proposed generic labeling.
The central defenses would ordinarily include noninfringement, invalidity under Sections 101, 102 and 103 of the Patent Act, lack of written description or enablement under Section 112, and possible attacks on the scope of method-of-use claims.
When does Cabometyx lose exclusivity?
Cabometyx does not have one single exclusivity date. Generic entry depends on the interaction of FDA regulatory exclusivity, Orange Book patents, pediatric exclusivity, court orders and any private settlement.
Regulatory exclusivity
Cabometyx received FDA approval in 2012. The product’s original new-drug exclusivity period has expired. Cabometyx therefore relies primarily on patent protection and related Hatch-Waxman litigation risk rather than unexpired small-molecule regulatory exclusivity.
Patent exclusivity
The earliest foundational cabozantinib patents expire before the latest formulation and method patents. Public patent records and Orange Book information show that the commercial protection period is divided across multiple patents rather than governed by one terminal date.
The practical entry date may therefore be:
- the expiration date of the last enforceable patent covering the generic product;
- an earlier date negotiated in a settlement;
- an earlier date resulting from a successful invalidity or noninfringement judgment; or
- a later date if regulatory, manufacturing or supply conditions delay launch.
A patent’s nominal expiration date is not the same as guaranteed market exclusivity. Patent-term adjustment, patent-term extension, pediatric exclusivity and claim-by-claim enforceability can change the effective result.
What was the litigation status of Exelixis v. Cipla?
The action was filed in the District of Delaware in 2023 after Cipla submitted an ANDA containing Paragraph IV certifications directed to Cabometyx patents. Exelixis sued Cipla under the Hatch-Waxman framework, seeking relief that would prevent commercial approval or launch of the proposed generic product before the relevant patent protections expired.
The case did not proceed to a publicly reported merits decision. The parties later filed papers ending the action pursuant to a negotiated resolution. The case’s disposition means that the docket does not provide a judicial determination that the asserted patents were valid, infringed or enforceable.
Litigation timeline
| Event |
Timing |
| Cipla ANDA challenge |
Before the 2023 complaint |
| Exelixis complaint |
2023 |
| Federal case |
1:23-cv-00287 |
| Court |
U.S. District Court for the District of Delaware |
| Primary dispute |
Cabometyx patent infringement under Hatch-Waxman |
| Merits trial |
No public trial judgment identified |
| Resolution |
Settlement-related dismissal |
| Settlement terms |
Not publicly stated in the docket |
The dismissal should not be treated as a finding that Cipla’s ANDA infringed the asserted patents. It also does not establish that the patents would have survived invalidity challenges. The economic effect depends on the confidential settlement terms, particularly any license, launch date, royalty arrangement, supply obligation or restriction on authorized-generic competition.
Did Cipla obtain a license or an agreed generic launch date?
The public dismissal record does not disclose the material business terms of the Exelixis-Cipla resolution. There is no public basis to assign Cipla a specific authorized launch date, royalty rate or launch restriction from the case docket alone.
In pharmaceutical patent settlements, the commercially material provisions commonly include:
- a license beginning before or on patent expiration;
- a defined generic launch date;
- a royalty or other payment structure;
- a no-challenge covenant;
- an authorized-generic arrangement;
- restrictions on product strengths or indications; and
- obligations concerning manufacturing, supply or labeling.
The absence of public terms limits the ability to calculate Cipla’s precise competitive impact. The dismissal establishes that the litigation ended, but it does not disclose whether Exelixis preserved a full patent-barrier period or traded an earlier controlled entry for commercial certainty.
What generic entry risks exist for Cabometyx?
Cabometyx faces a layered generic-entry risk rather than a single challenger risk. Cipla’s case demonstrates that at least one manufacturer was willing to accept Paragraph IV litigation exposure. Other ANDA applicants may pursue separate challenges against the same patents or rely on different claim constructions and invalidity theories.
Main entry scenarios
| Scenario |
Effect on Exelixis |
| Settlement with delayed launch |
Preserves revenue through the negotiated date but creates a known future erosion point |
| Early licensed entry |
May reduce litigation costs while accelerating price competition |
| Patent invalidation |
Could permit multiple generic launches before the nominal expiration of later patents |
| Noninfringement finding |
Could remove the asserted barrier for the challenger |
| Single-challenger settlement |
Leaves other ANDA applicants free to pursue independent litigation |
| Authorized generic launch |
Can reduce the price impact of an independent generic by allowing Exelixis to retain part of the value chain |
The most important technical issue is whether the asserted claims cover the product itself or only a labeled use. Product claims generally create broader entry barriers than method-of-use claims. Method claims can be weakened if the generic applicant uses a compliant skinny label that omits the patented indication, although inducement and label-content disputes can still arise.
How strong is the Exelixis Cabometyx patent estate?
The estate has meaningful structural strength because it includes multiple patent categories. Its risk profile is less clear where protection depends on narrow formulation limitations or use-specific claims.
Strengths
- Multiple patents can raise the cost of a Paragraph IV challenge.
- Formulation and salt-related claims can supplement earlier compound patents.
- Method-of-use patents may cover commercially important oncology indications.
- Orange Book-listed patents create an automatic regulatory stay after a timely infringement suit.
- A settlement avoids the risk of an adverse claim-construction or invalidity ruling.
Weaknesses
- Later patents may face obviousness challenges if they claim routine formulation choices or predictable dosing regimens.
- Method-of-use claims can be vulnerable to skinny-label strategies.
- Several patents may share overlapping disclosures, allowing challengers to attack written-description, enablement or obviousness issues across the family.
- Settlement does not validate the estate.
- Generic applicants can challenge different patent families at different times.
The estate is stronger as a portfolio than as a single patent. Its commercial value depends on the enforceability of the specific claims listed against each ANDA and on whether the proposed generic product practices those claims.
What patent litigation affects Cabometyx and competing oncology drugs?
Cabometyx competes in treatment areas that include renal cell carcinoma and hepatocellular carcinoma. The competitive landscape includes other targeted therapies and immuno-oncology combinations, including products marketed by Bristol Myers Squibb, Merck, Roche, Novartis and Pfizer.
Patent risk differs by product type:
| Product category |
Typical protection profile |
| Small-molecule kinase inhibitor |
Compound, salt, formulation and method patents |
| Combination regimen |
Method-of-use and dosing patents |
| Monoclonal antibody |
Composition, sequence, formulation and manufacturing patents |
| Cell or gene therapy |
Platform, vector, manufacturing and treatment patents |
Cabometyx is a small molecule, so biosimilar risk does not apply directly. A biosimilar cannot be filed for cabozantinib under the Public Health Service Act. The relevant competitive threat is an ANDA-based generic, not a biosimilar. Manufacturing barriers are also more limited than for biologics, although control of the active ingredient, salt form, tablet process and quality system can affect launch timing.
What is the likely commercial impact of Cipla’s case?
Exelixis has historically generated substantial revenue from Cabometyx, making generic entry a material portfolio event. A generic launch would likely cause rapid price erosion in the tablet market, although the magnitude would depend on the number of approved entrants, payer substitution, channel contracts and whether Exelixis launches an authorized generic.
The commercial impact would be lower if Cipla’s settlement permits only a late launch or limits its approved labeling. It would be higher if the settlement allows entry before the expiration of the most commercially important Orange Book patents or if other challengers launch concurrently.
For valuation purposes, the key variables are:
- the confidential Cipla launch date;
- the number of other ANDA applicants;
- the last enforceable patent covering the most valuable indications;
- the probability of an authorized generic;
- Cabometyx sales concentration by indication;
- price erosion after the first and second generic entrants; and
- Exelixis’s ability to shift patients to newer products or combination regimens.
Key Takeaways
- Exelixis v. Cipla, No. 1:23-cv-00287, was a Delaware Hatch-Waxman action involving Cipla’s proposed generic cabozantinib tablets.
- Exelixis asserted Cabometyx-related patent rights after Cipla filed an ANDA with Paragraph IV certifications.
- The case ended through a negotiated dismissal, not a public merits judgment.
- The docket does not disclose Cipla’s launch date, royalty obligations or other settlement terms.
- Cabometyx’s protection comes from a portfolio of compound, formulation, salt and method-of-use patents.
- Cabozantinib is a small molecule, so biosimilar substitution is not the relevant risk. Generic ANDA entry is.
- The settlement reduces immediate litigation uncertainty but does not establish that Exelixis’s patents would have survived trial.
- Future revenue exposure depends on Cipla’s confidential launch terms and the activity of other generic challengers.
FAQs
Does the Cipla case mean Cabometyx patents were upheld?
No. The case ended without a public validity, infringement or enforceability judgment.
Can Cipla launch generic Cabometyx immediately after dismissal?
Not necessarily. A dismissal does not itself establish FDA approval or a launch right. Any launch would depend on Cipla’s ANDA status, applicable patents and the settlement terms.
Is cabozantinib subject to biosimilar competition?
No. Cabozantinib is a small-molecule drug regulated through the ANDA pathway. Generic competition, rather than biosimilar competition, is the relevant threat.
Does a Paragraph IV settlement always reveal the generic launch date?
No. Pharmaceutical settlement agreements are often confidential. The public docket may disclose only that the litigation was dismissed.
Could another generic company challenge Cabometyx after Cipla’s case ended?
Yes. A separate ANDA applicant can bring an independent Paragraph IV challenge against Orange Book-listed patents, subject to the statutory framework and any applicable exclusivity rights.
References
-
U.S. District Court for the District of Delaware. (2023). Exelixis, Inc. v. Cipla Ltd., No. 1:23-cv-00287. PACER/CourtListener docket.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
-
U.S. Food and Drug Administration. (n.d.). Cabometyx prescribing information. FDA.
-
U.S. Patent and Trademark Office. (n.d.). Patent Center. U.S. Department of Commerce.
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications. FDA.
